DE10228680A1 - Grundlage für transdermale Formulierungen (PTF) - Google Patents
Grundlage für transdermale Formulierungen (PTF) Download PDFInfo
- Publication number
- DE10228680A1 DE10228680A1 DE10228680A DE10228680A DE10228680A1 DE 10228680 A1 DE10228680 A1 DE 10228680A1 DE 10228680 A DE10228680 A DE 10228680A DE 10228680 A DE10228680 A DE 10228680A DE 10228680 A1 DE10228680 A1 DE 10228680A1
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- oily emulsion
- transdermal administration
- composition
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000009472 formulation Methods 0.000 title description 12
- 239000000839 emulsion Substances 0.000 claims abstract description 33
- 235000015097 nutrients Nutrition 0.000 claims abstract description 12
- 239000013543 active substance Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000000787 lecithin Substances 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 12
- 239000003833 bile salt Substances 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 229940093761 bile salts Drugs 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- JEUAKJVLHISJDY-UHFFFAOYSA-N 2,3-dimethylthiolane 1,1-dioxide Chemical compound CC1CCS(=O)(=O)C1C JEUAKJVLHISJDY-UHFFFAOYSA-N 0.000 claims description 2
- WKFQMDFSDQFAIC-UHFFFAOYSA-N 2,4-dimethylthiolane 1,1-dioxide Chemical compound CC1CC(C)S(=O)(=O)C1 WKFQMDFSDQFAIC-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 102000004877 Insulin Human genes 0.000 description 32
- 108090001061 Insulin Proteins 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- CWYNVVGOOAEACU-UHFFFAOYSA-N iron (II) ion Substances [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- ITYLKCDBOWEVQX-DFWYDOINSA-L (2s)-2-aminopentanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@@H](N)CCC([O-])=O ITYLKCDBOWEVQX-DFWYDOINSA-L 0.000 description 1
- 101800003158 5 kDa peptide Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10228680A DE10228680A1 (de) | 2002-06-27 | 2002-06-27 | Grundlage für transdermale Formulierungen (PTF) |
| JP2004517161A JP2005535635A (ja) | 2002-06-27 | 2003-06-21 | 経皮的組成物用プラットフォーム（ｐｔｆ） |
| US10/511,463 US20050118241A1 (en) | 2002-06-27 | 2003-06-21 | Platform for transdermal formulations (ptf) |
| AU2003252459A AU2003252459A1 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
| EP03761748A EP1515706A2 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
| CA002490022A CA2490022A1 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
| KR1020047021277A KR20050027995A (ko) | 2002-06-27 | 2003-06-21 | 경피적 조제물용 플랫폼(ｐｔｆ) |
| MXPA04012732A MXPA04012732A (es) | 2002-06-27 | 2003-06-21 | Plataforma para formulaciones transdermicas (pft). |
| CN038151030A CN1665492A (zh) | 2002-06-27 | 2003-06-21 | 用于经皮配方的平台(ptf) |
| PCT/IB2003/003467 WO2004002444A2 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
| TW092116951A TW200500093A (en) | 2002-06-27 | 2003-06-23 | A platform for transdermal formulations (PTF) |
| MYPI20032357A MY157852A (en) | 2002-06-27 | 2003-06-24 | A platform for transdermal formulations (ptf) |
| ARP030102324A AR040287A1 (es) | 2002-06-27 | 2003-06-27 | Plataforma para formulaciones transdermicas (pft) |
| ZA200500710A ZA200500710B (en) | 2002-06-27 | 2005-01-03 | A platform for transdermal formulations (PTF). |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10228680A DE10228680A1 (de) | 2002-06-27 | 2002-06-27 | Grundlage für transdermale Formulierungen (PTF) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10228680A1 true DE10228680A1 (de) | 2004-01-22 |
Family
ID=29761469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10228680A Withdrawn DE10228680A1 (de) | 2002-06-27 | 2002-06-27 | Grundlage für transdermale Formulierungen (PTF) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050118241A1 (enExample) |
| EP (1) | EP1515706A2 (enExample) |
| JP (1) | JP2005535635A (enExample) |
| KR (1) | KR20050027995A (enExample) |
| CN (1) | CN1665492A (enExample) |
| AR (1) | AR040287A1 (enExample) |
| AU (1) | AU2003252459A1 (enExample) |
| CA (1) | CA2490022A1 (enExample) |
| DE (1) | DE10228680A1 (enExample) |
| MX (1) | MXPA04012732A (enExample) |
| MY (1) | MY157852A (enExample) |
| TW (1) | TW200500093A (enExample) |
| WO (1) | WO2004002444A2 (enExample) |
| ZA (1) | ZA200500710B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
| WO2005094210A2 (en) * | 2004-03-12 | 2005-10-13 | The Hartz Mountain Corporation | Multi-action anthelmintic formulations |
| US10042980B2 (en) | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US20120283332A1 (en) * | 2009-05-12 | 2012-11-08 | Ohio University | Transdermal delivery of metformin |
| EP2437738B1 (en) * | 2009-06-05 | 2018-08-08 | Joan M. Caron | Methods and compositions for the treatment of cancer |
| JP6444865B2 (ja) | 2012-07-30 | 2018-12-26 | マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド | ダイズホスファチジルセリンで作られたコクリエート |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011705A1 (en) * | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4878892A (en) * | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| FR2616333A1 (fr) * | 1987-06-12 | 1988-12-16 | Cird | Procede d'ionophorese pour administrer une substance dissoute ou partiellement dissoute, par voie percutanee ou perungueale et dispositif correspondant |
| JPS63316737A (ja) * | 1987-06-19 | 1988-12-26 | Toyo Jozo Co Ltd | 経鼻投与用医薬組成物 |
| IT1223343B (it) * | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| US5332577A (en) * | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
| EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
| US5073539A (en) * | 1990-01-22 | 1991-12-17 | Ciba-Geigy Corporation | Transdermal administration of zwitterionic drugs |
| JPH06509577A (ja) * | 1991-07-26 | 1994-10-27 | スミスクライン・ビーチャム・コーポレイション | Ｗ／ｏミクロエマルジョン |
| FR2687321B1 (fr) * | 1992-02-14 | 1999-04-16 | Elf Aquitaine | Dispositif d'ionophorese pour l'administration transcutanee d'une quantite totale donnee d'un principe actif a un sujet. |
| EP0739644A4 (en) * | 1994-09-30 | 1998-12-09 | Advance Kk | INTERFACE FOR A TRANSDERMAL IONTOPHORETIC DEVICE AND CORRECT MEDICINE |
| US5759445A (en) * | 1995-05-24 | 1998-06-02 | Matsushita Electric Industrial Co., Ltd. | Lipid-dispersed solution and process for producing the same |
| US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
| DE69939019D1 (de) * | 1998-07-07 | 2008-08-14 | Transdermal Technologies Inc | Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung |
| WO2000067728A2 (de) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Lipidpartikel auf der basis von mischungen von flüssigen und festen lipiden und verfahren zu ihrer herstellung |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
-
2002
- 2002-06-27 DE DE10228680A patent/DE10228680A1/de not_active Withdrawn
-
2003
- 2003-06-21 AU AU2003252459A patent/AU2003252459A1/en not_active Abandoned
- 2003-06-21 US US10/511,463 patent/US20050118241A1/en not_active Abandoned
- 2003-06-21 JP JP2004517161A patent/JP2005535635A/ja active Pending
- 2003-06-21 EP EP03761748A patent/EP1515706A2/en not_active Withdrawn
- 2003-06-21 CN CN038151030A patent/CN1665492A/zh active Pending
- 2003-06-21 CA CA002490022A patent/CA2490022A1/en not_active Abandoned
- 2003-06-21 KR KR1020047021277A patent/KR20050027995A/ko not_active Withdrawn
- 2003-06-21 MX MXPA04012732A patent/MXPA04012732A/es not_active Application Discontinuation
- 2003-06-21 WO PCT/IB2003/003467 patent/WO2004002444A2/en not_active Ceased
- 2003-06-23 TW TW092116951A patent/TW200500093A/zh unknown
- 2003-06-24 MY MYPI20032357A patent/MY157852A/en unknown
- 2003-06-27 AR ARP030102324A patent/AR040287A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 ZA ZA200500710A patent/ZA200500710B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011705A1 (en) * | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004002444A2 (en) | 2004-01-08 |
| MXPA04012732A (es) | 2005-11-17 |
| ZA200500710B (en) | 2005-09-05 |
| KR20050027995A (ko) | 2005-03-21 |
| AU2003252459A1 (en) | 2004-01-19 |
| WO2004002444A3 (en) | 2004-03-11 |
| CA2490022A1 (en) | 2004-01-08 |
| EP1515706A2 (en) | 2005-03-23 |
| JP2005535635A (ja) | 2005-11-24 |
| AR040287A1 (es) | 2005-03-23 |
| TW200500093A (en) | 2005-01-01 |
| CN1665492A (zh) | 2005-09-07 |
| US20050118241A1 (en) | 2005-06-02 |
| MY157852A (en) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3528979C2 (enExample) | ||
| DE69722793T2 (de) | Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren | |
| DE69909794T2 (de) | Verwendung eines dipeptids für wiederherstellungsprozesse | |
| DE69126609T2 (de) | Pharmazeutische formulierungen | |
| DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
| DE69030095T2 (de) | Vorrichtung zum verabreichen von medikamenten auf schleimhautgewebe | |
| DE69523295T2 (de) | Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung | |
| DE69735949T2 (de) | Zusammensetzung geeignet zur behandlung der pferdelahmheit | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| DE112013001457T5 (de) | Transdermales Applikationssystem | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE69300608T2 (de) | Verwendung von L-Deprenyl zur Herstellung eines Arzneimittels zur Behandlung der Cushing's-Krankheit. | |
| CN1141929C (zh) | 药物制剂 | |
| EP0697869B1 (de) | Transdermale therapeutische systeme zur verabreichung von serotoninagonisten | |
| DE69614419T2 (de) | Transdermale Formulierung eines Mittels muscarinischer Wirkung | |
| DE3883606T2 (de) | Verwendung von Fluoxetin zur Behandlung des Diabetes. | |
| DE3727585C2 (de) | Nicorandil enthaltende Arzneimittel zur äußeren Anwendung | |
| DE69021415T2 (de) | Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen. | |
| DE10228680A1 (de) | Grundlage für transdermale Formulierungen (PTF) | |
| DE4305881C1 (de) | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE69422637T2 (de) | Transdermale zusammensetzung von n-(n-(5-(4-(aminoiminomethyl)phenyl-1-oxopentyl)-l-alpha-aspartyl)-l-phenylalanin oder deren esterderivaten und ihre pharmazeutischverwendbaren salze | |
| DE69710918T2 (de) | Topisches präparat zur abgabe eines peptidarzneimittels in lebewesen | |
| DE3851389T2 (de) | Liposom-Freisetzungssystem für Opoid-Analgetika. | |
| EP0001124A1 (de) | Neue Arzneimittelmischungen zur Verbesserung der Glucoseverwertung in den Zellen und Senkung des Blutzuckerspiegels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |